The trial was funded by Receptos. Dr. Bar-Or reported receiving financial support from Biogen Idec, DioGenix, Genentech, GlaxoSmithKline, Guthy-Jackson Charitable Foundation, MedImmune, Merck Serono, Novartis, Ono Pharmaceuticals, Receptos, Roche, Sanofi-Aventis, and Teva Neuroscience.
Conference Coverage
Phase II RADIANCE study results demonstrate efficacy of RPC1036 in MS
Publish date: September 17, 2014
AT MSBOSTON 2014